<?xml version='1.0' encoding='utf-8'?>
<document id="30730615"><sentence text="A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels." /><sentence text="ASP8477 (molecular weight 325" /><sentence text="36 g/mol) is a fatty acid amide hydrolase inhibitor intended for the treatment of neuropathic pain"><entity charOffset="15-31" id="DDI-PubMed.30730615.s3.e0" text="fatty acid amide" /></sentence><sentence text=" Results from in vitro studies indicated that ASP8477 is a direct inhibitor of cytochrome P450 (CYP) 2C8, 2C9, 2C19, 2D6, and 3A4 enzymes at expected efficacious concentrations, with the strongest effect on CYP2C19; a phase 1 study confirmed ASP8477 to be a CYP2C19 inhibitor" /><sentence text=" To further evaluate the interaction potential of ASP8477, a cocktail interaction study was performed using the probe substrates of the validated Inje cocktail containing losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4)"><entity charOffset="171-179" id="DDI-PubMed.30730615.s5.e0" text="losartan" /><entity charOffset="181-187" id="DDI-PubMed.30730615.s5.e1" text="CYP2C9" /><entity charOffset="190-200" id="DDI-PubMed.30730615.s5.e2" text="omeprazole" /><entity charOffset="202-209" id="DDI-PubMed.30730615.s5.e3" text="CYP2C19" /><entity charOffset="212-228" id="DDI-PubMed.30730615.s5.e4" text="dextromethorphan" /><entity charOffset="230-236" id="DDI-PubMed.30730615.s5.e5" text="CYP2D6" /><entity charOffset="243-252" id="DDI-PubMed.30730615.s5.e6" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e0" e2="DDI-PubMed.30730615.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e0" e2="DDI-PubMed.30730615.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e0" e2="DDI-PubMed.30730615.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e0" e2="DDI-PubMed.30730615.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e0" e2="DDI-PubMed.30730615.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e0" e2="DDI-PubMed.30730615.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e0" e2="DDI-PubMed.30730615.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e1" e2="DDI-PubMed.30730615.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e1" e2="DDI-PubMed.30730615.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e1" e2="DDI-PubMed.30730615.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e1" e2="DDI-PubMed.30730615.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e1" e2="DDI-PubMed.30730615.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e1" e2="DDI-PubMed.30730615.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e2" e2="DDI-PubMed.30730615.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e2" e2="DDI-PubMed.30730615.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e2" e2="DDI-PubMed.30730615.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e2" e2="DDI-PubMed.30730615.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e2" e2="DDI-PubMed.30730615.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e3" e2="DDI-PubMed.30730615.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e3" e2="DDI-PubMed.30730615.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e3" e2="DDI-PubMed.30730615.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e3" e2="DDI-PubMed.30730615.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e4" e2="DDI-PubMed.30730615.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e4" e2="DDI-PubMed.30730615.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e4" e2="DDI-PubMed.30730615.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e5" e2="DDI-PubMed.30730615.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30730615.s5.e5" e2="DDI-PubMed.30730615.s5.e6" /></sentence><sentence text=" Because ASP8477 shows nonlinear pharmacokinetics, 3 doses (20, 60, and 100 mg) were evaluated" /><sentence text=" This study revealed changes in exposure (area under the concentration-time curve) of the probe substrates after treatment with 20, 60, and 100 mg ASP8477, respectively, compared with substrates alone with geometric mean ratios of: midazolam, 119%, 151%, and 158%; losartan, 107%, 144%, and 190%; omeprazole, 213%, 456%, and 610%; and dextromethorphan, 138%, 340%, and 555% (with increasing doses, respectively)"><entity charOffset="232-241" id="DDI-PubMed.30730615.s7.e0" text="midazolam" /><entity charOffset="265-273" id="DDI-PubMed.30730615.s7.e1" text="losartan" /><entity charOffset="297-307" id="DDI-PubMed.30730615.s7.e2" text="omeprazole" /><entity charOffset="335-351" id="DDI-PubMed.30730615.s7.e3" text="dextromethorphan" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e0" e2="DDI-PubMed.30730615.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e0" e2="DDI-PubMed.30730615.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e0" e2="DDI-PubMed.30730615.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e0" e2="DDI-PubMed.30730615.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e1" e2="DDI-PubMed.30730615.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e1" e2="DDI-PubMed.30730615.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e1" e2="DDI-PubMed.30730615.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e2" e2="DDI-PubMed.30730615.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30730615.s7.e2" e2="DDI-PubMed.30730615.s7.e3" /></sentence><sentence text=" Overall, ASP8477 was a weak inhibitor for CYP3A4 and CYP2C9, a moderate to strong inhibitor for CYP2C19, and a weak to strong inhibitor for CYP2D6, with doses from 20 to 100 mg" /><sentence text=" This study confirmed that the Inje cocktail approach was able to detect relevant drug-drug interactions impacting further development of ASP8477 and future therapeutic use" /><sentence text=" With the approach used here, the inhibiting effect of a perpetrator drug on different CYP enzymes can be evaluated, and at different doses, thereby supporting dose recommendations for potential interactions" /><sentence text="" /></document>